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1. INTRODUCTION 
1.1. ANALYTICAL METHOD DEVELOPMENT  
HPLC method development and validation is important for the analysis of drugs in any 
formulation. The method which is used for quantitation or identification of drug should be a 
validated one. It must be able to detect or quantitate the particular drug in the presence of 
other components. Before starting  any method development one should have knowledge 
about the information of nature of the sample, separation goals, number of compounds 
present, chemical structures, molecular weights, pKa values, solubility and UV spectrum of 
the compounds. Perhaps maximum method development involves the trial and error 
procedures.  
      The most difficult problem usually occurs in method development is where to start, what 
type of column is worth trying with what kind of mobile phase. While there are a number of 
HPLC methods available to the development chemist, perhaps the most commonly applied 
method is Reversed Phase Chromatography method.  
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A typical pharmaceutical compound is considered to be an active pharmaceutical 
ingredient (API) of less than 1000 Daltons, either soluble in water or in an organic solvent. 
The water soluble drug is further differentiated as ionic or nonionic which can be separated 
by reverse phase. Similarly, the organic soluble drugs can be classified as polar and non polar 
and equally separated by reverse phase. In some cases the non polar API may have to be 
separated using adsorption or normal phase HPLC, in which mobile phase would be non 
polar organic solvent. The other chromatographic modes may need to be considered for 
separation. These include ion exchange, chiral and size exclusion chromatography. Samples 
like proteins, peptides nucleic acids and synthetic polymers analyzed by using some special 
columns or ion pair reagents (i.e. 0.1% TFA). 
 
1.1.1. General conditions to initiate HPLC method development 
In general, one begins with reversed phase chromatography, when the compounds are 
hydrophilic in nature with many polar groups and are water soluble. The organic phase 
concentration required for the mobile phase can be estimated by gradient elution method. For 
aqueous sample mixtures, the best way to start is with gradient reversed phase 
chromatography. Gradient can be started with 5-10% organic phase in the mobile phase and 
the organic phase concentration can be increased up to 100% within 20-30 min. Separation 
can be optimized by changing the initial mobile phase composition and the slope of gradient 
according to the chromatogram obtained from preliminary sample run. The initial mobile 
phase composition can be estimated on the basis of where the compounds of interest were 
eluted, namely at what mobile phase composition. Changing the polarity of a mobile phase 
can alter elution of drug molecules.  
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Table-1: Column & mobile phase selection shall be done as per the table given below 
Method/Description/Column When the method preferred 
Reverse-Phase HPLC 
Water/organic mobile phase 
For neutral and non ionized compounds 
that dissolve in water/organic mixtures. 
Column: C18,C8,Phenyl,Cyano, and Trimethylsilys (TMS) columns. 
Normal Phase HPLC 
Mixture of organic solvents as mobile 
phase 
For samples that do not dissolve in 
water/organic mixture. 
Column: Silica, Cyano and Amino columns. 
 
 
     The elution strength of a mobile phase depends upon its polarity, the stronger the polarity, 
higher is the elution. Ionic samples (acidic and basic) can be separated, if they are present in 
associated form. Dissociation of ionic samples may be suppressed by proper selection of pH. 
The optimized chromatogram is the one in which all the peaks are symmetrical and are well 
separated in less run time. 
 
The peak resolution can be increased by using a more efficient column (column with 
higher theoretical plate number), which can be achieved by using a column of smaller 
particle size, or a longer column in length. These factors will increase the analysis time. Flow 
rate does not influence resolution, but it has a strong effect on the analysis time. 
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The parameter that are affected by the changes in chromatographic conditions are, 
 Capacity factor (K’). 
 Selectivity (α). 
 Column efficiency (N). 
 Peak asymmetry factor or Tailing factor (As). 
 
 1.1.2. Selection of mobile phase 
The selection of the mobile phase mainly based on the solubility and polarity of the 
compound. Usually, in RP-HPLC method water and organic solvents are used as the mobile 
phase. In NP-HPLC method non polar solvents like Hexane and THF were used. If the 
sample contains ionic or ionizable compounds, then use of a buffered mobile phase to ensure 
the reproducible results.  
In many cases, a silanophilic interaction causes tailing, mainly for the basic compounds 
due to ion-exchange interaction. This can usually be reduced or suppressed by the use of 
mobile phases modifiers (0.1% v/v triethylamine for basic analyte or 1% v/v glacial acetic 
acid for the acidic analyte), or a combination thereof. Whenever buffers or other mobile 
phase are used, check the solubility in mobile phase. This is especially true for gradient 
applications. Acetonitrile is the preferred organic modifier in reversed phase chromatography. 
The elution strength increases in the order methanol, acetonitrile and tetrahydrofuran. The 
retention changes by roughly 10% for every 1% change in the concentration of organic 
modifier. 
1.1.3. Mobile phase composition 
In reverse phase chromatography, the separation is mainly controlled by the hydrophobic 
interaction between drugs molecules and the alkyl chains on the column packing materials. 
Most chromatographic separation can be achieved by choosing the optimum mobile phase 
composition. This is due to the fact that a fairly large amount of selectivity can be achieved 
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by choosing the qualitative and quantitative composition of aqueous and organic 
portions.Most widely used solvents in reverse phase chromatography are Methanol and 
Acetonitrile. Tetrahydrofuran is also used but to a lesser extent. 
 A drug solution having all possible known impurities can be used for checking the 
extent of separation with different mobile phase ratios. Alternatively, solution of stressed 
drug substance can be used to check for separation of impurities.Silica based column with 
different crosslinkings in the increasing order of polarity are as follows. 
<-----Non-polar-----Moderately polar----Polar-----> 
C18<C8<C6<Phenyl<Amino<Cyano<Silica. 
 Experiments are to be conducted using different columns with different mobile phase to 
achieve best separation in chromatography. A column which gives separation of all the 
individual impurities and degradants from each other and from API peak and which is rugged 
for variation in mobile phase shall be selected. 
 
1.1.4. Selection of column 
The HPLC column is the heart of the method, performing the critical separation. The 
column must possess the selectivity, efficiency and reproducibility to provide good 
separation. Commonly used reversed phases are crosslinking the Si-OH groups with alkyl 
chains like, C8 (octylsilane), C18 (octadecylsilane) and nitrile groups (CN), phenyl groups (-
C6H6) and amino groups (-NH2). They are chemically different bounded phases and 
demonstrate significant changes in the selectivity using the same mobile phase. During 
method development selection of column can be streamlined by starting with shorter column 
(150, 100 or even 50 mm long). By selecting a shorter column with an appropriate phase run 
time can be minimized so that an elution order and an optimum mobile phase can be quickly 
determined. The following are the parameters of a chromatographic column which are to be 
considered while choosing a column for separation of impurities and degradants.  
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 Length and diameter of the column.  
 Packing material. 
 Shape of the particles.  
 Size of the particles.  
 % of carbon loading.  
 Pore volume.  
 Surface area.  
 End capping. 
1.1.5. Selection of Column temperature 
Temperature variation over the course of a day has quite significant effect on HPLC 
separations. This can even occur in air conditioned rooms. While temperature is a variable 
that can affect the selectivity, its effect is relatively small. Always it is preferable to optimize 
the chromatographic conditions with column temperature as ambient.  However, if the peak 
is symmetry could not be achieved by any combination of column and mobile phase, then the 
column temperatures above ambient can be adopted. The increase in column temperature 
generally will result in reduction in peak asymmetry and peak retentions. When found 
necessary, the column temperatures between 30ºC and 80ºC shall be adopted. If a column 
temperature of above 80ºC is found to be necessary, packing materials which can withstand 
to that temperature shall be chosen. 
 
1.1.6. Selection of flow rate 
Flow rate, more for isocratic than gradient separation, can sometimes be useful and 
readily utilized to increase the resolution, although its effect is very modest. The slower flow 
rate will also decrease the column back pressure.  
Flow rate shall be selected bases on the following data.  
 Retention times.  
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 Column back pressures 
 Separation of impurities. 
 Peak symmetries.  
Preferably the flow rate shall be not more than 2.5 ml/min. check the ruggedness of the 
method by varying the flow rate by ± 0.2 ml from the selected flow rate. Select the flow rate 
which gives least retention times, good peak symmetries, least back pressures and better 
separation of impurities from each other and from API peak. 
The mobile phases are pumped at different flow rates so as to achieve the required 
composition and then mixed in a chamber and then introduced into the column. While 
optimizing the separation of impurities, it is to be decided whether Low-pressure gradient 
[not more than 80% organic phase is to be pumped] or High-pressure gradient [more than 
80% of the organic phase is to be pumped]. While optimizing the gradient program, 
especially using low viscous solvents like acetonitrile and phosphate buffers, it is 
recommended to mix about 10% aqueous portion preferably the same buffer used in mobile 
phase to avoid pumping problems. 
1.1.7. Selection of detector wavelength  
Selection of detector wavelength is a critical step in finalization of the analytical method 
for impurities and degradants. Inject the impurity and API standard solutions into the 
chromatographic system with photodiode array detector and collect the spectra. Also conduct 
forced degradation studies and collect the UV spectra of all the major degradation products. 
Overlay the spectra of all the compounds and select a wavelength which is most common and 
gives higher responses for all compounds. 
1.1.8. Selection of Diluents for Test preparation  
Diluent for test preparation is selected initially based on solubility of the drug substances 
and known impurities.Finalization of diluent is based on its extraction efficiency peak 
symmetries and resolution of Impurities and diluent blank injection interference. Inject the 
diluent blank and test solution spiked with known impurities into the chromatographic 
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system and establish the non-interference of blank in estimation of impurities and the effect 
of diluent on resolution of impurities and peak symmetries. 
    Conduct experiments to optimize the extraction of API in presence of recipients at 
different test concentrations using the diluent chosen based on solubility and select the test 
concentration at which the extraction is most efficient. Select a diluent in which all the 
known impurities/degradants and drug substances are soluble, in which the extraction is 
complete, due to which there is no blank interference, in which the peak symmetries and 
resolution between impurities is found to be satisfactory. 
1.1.9. Selection of Test concentration, Injection volume  
The test concentration is generally chosen based upon the response of API peak and 
impurities at the selected detector wavelength. The test concentration shall be finalized after 
it is proved that API is completely extractable at the selected test concentration. Generally an 
injection volume of 10 to 20µl is recommended for estimation of impurities.   
    If the extractions are found to be difficult, then the test concentrations can be kept low and 
the injection volume can be increase up to 50 µl but it is to be ensured that at the selected 
injection volume the column is not overloaded, resolution between individual impurities and 
the peak symmetries are not compromised. After the test concentration and the diluent is 
finalized, prepare a test solution and keep the filtered solution in closed condition in a 
stoppered flask on the bench top and observe for any precipitation or turbidity after 24 hours.  
The solution should not show any turbidity/precipitation. 
 
1.2.ANALYTICAL METHOD VALIDATION
4 
1.2.1. Types of Analytical Procedures to be validated  
The validation of analytical procedures is directed to the four most common types of 
analytical procedures. 
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 Identification tests 
 Quantitative tests for impurities' content 
 Limit tests for the control of impurities 
 Quantitative tests of the active moiety in samples of drug substance or drug 
product or other selected component(s) in the drug product.  
The objective of the analytical procedure should be clearly understood since this will 
govern the validation characteristics which need to be evaluated. Typical validation 
characteristics which should be considered are listed below. 
 Accuracy  
 Precision  
 Repeatability  
 Intermediate Precision  
 Specificity  
 Detection Limit  
 Quantitation Limit  
 Linearity  
 Range 
This list should be considered typical for the analytical procedures cited but occasional 
exceptions should be dealt with on a case-by-case basis. It should be noted that robustness is 
not listed but should be considered at an appropriate stage in the development of the 
analytical procedure. 
Furthermore revalidation may be necessary in the following circumstances  
 Changes in the synthesis of the drug substance.  
 Changes in the composition of the finished product.  
 Changes in the analytical procedure.  
The degree of revalidation required depends on the nature of the changes. Certain other 
changes may require validation as well. 
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1.2.2. Specificity  
Specificity is the ability to assess unequivocally the analyte in the presence of 
components which may be expected to be present. Typically these might include impurities, 
degradants, matrix, etc. Lack of specificity of an individual analytical procedure may be 
compensated by other supporting analytical procedure(s).  
This definition has the following implications:  
Identification: to ensure the identity of an analyte. 
Purity Tests: to ensure that all the analytical procedures performed allow an accurate 
statement of the content of impurities of an analyte, i.e. related substances test, heavy metals, 
residual solvents content, etc.  
Assay (content or potency): to provide an exact result which allows an accurate statement on 
the content or potency of the analyte in a sample.  
1.2.3. Accuracy   
The accuracy of an analytical procedure expresses the closeness of agreement between 
the value which is accepted either as a conventional true value or an accepted reference value 
and the value found. This is sometimes termed trueness.  
1.2.4. Precision  
The precision of an analytical procedure expresses the closeness of agreement (degree of 
scatter) between a series of measurements obtained from multiple sampling of the same 
homogeneous sample under the prescribed conditions. Precision may be considered at three 
levels: repeatability, intermediate precision and reproducibility. Precision should be 
investigated using homogeneous, authentic samples. However, if it is not possible to obtain a 
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homogeneous sample it may be investigated using artificially prepared samples or a sample 
solution.  
The precision of an analytical procedure is usually expressed as the variance, standard 
deviation or coefficient of variation of a series of measurements.  
Repeatability: Repeatability expresses the precision under the same operating conditions over 
a short interval of time. Repeatability is also termed intra-assay precision. 
Intermediate precision: Intermediate precision expresses within-laboratories variations: 
different days, different analysts, different equipment, etc.  
Reproducibility: Reproducibility expresses the precision between laboratories (collaborative 
studies, usually applied to standardization of methodology). 
1.2.5. Detection limit  
The detection limit of an individual analytical procedure is the lowest amount of analyte 
in a sample which can be detected but not necessarily quantitated as an exact value. 
1.2.6. Quantitation limit  
The quantitation limit of an individual analytical procedure is the lowest amount of 
analyte in a sample which can be quantitatively determined with suitable precision and 
accuracy. The quantitation limit is a parameter of quantitative assays for low levels of 
compounds in sample matrices, and is used particularly for the determination of impurities 
and/or degradation products. 
 1.2.7. Linearity  
The linearity of an analytical procedure is its ability (within a given range) to obtain test 
results which are directly proportional to the concentration (amount) of analyte in the sample. 
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1.2.8. Range  
The range of an analytical procedure is the interval between the upper and lower 
concentration (amounts) of analyte in the sample (including these concentrations) for which 
it has been demonstrated that the analytical procedure has a suitable level of precision, 
accuracy and linearity.  
1.2.9. Robustness  
The robustness of an analytical procedure is a measure of its capacity to remain 
unaffected by small, but deliberate variations in method parameters and provides an 
indication of its reliability during normal usage. 
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2. REVIEW OF LITERATURE 
2.1. Hassan Y.Aboul-Enein, et al
5
,(2011) validated enantioselective HPLC assay of 
dexibuprofen tablet formulations. Mobile phase was composed of 0.025 M potassium 
phosphate dibasic (pH 4.5) – methanol- ethanol ( 85:10:5 v/v/v).The method was linear 
over the range 15-35 µg/ml (r
2
= 0.9995) ; accuracy and precision were acceptable with % 
RSD < 2.0%. 
2.2. P.Balan, et al
6
,(2011) validated Rp-HPLC Method for estimation of 
dexibuprofen and paracetamol in combined tablet dosage form. The method was carried 
out on a C-18 ,250× 4.5 mm consisting of acetonitrile: water  in ratio of  50:50 (pH-7.8  
adjusted with triethylamine ) as mobile phase at a flow rate of 1.0 ml/ min. Detection was 
carried out at 230nm. The retention times of   dexibuprofen and paracetamol were found 
to be 1.7 and 2.4 .Linear in the range of 2-10 µg/ml for dexibuprofen and paracetamol. 
2.3. SelvaduraiMuralidharan, et al
7
,(2011) developed the validation of HPLC and 
an UV Spectrophotometric Methods for determination of Dexibuprofen in pharmaceutical 
Preparations. Mobile phase was composed of acetonitrile and 0.5% triethylamine (pH 
adjusted with ortophosphoric acid (30:70,v/v)) with RP-18 column .UV was performed at 
222 nm. No spectral or chromatographic interferences from the tablet excipients were 
found in UV and HPLC. 
2.4. Pritesh G. Dhartarkar, et al
8
,(2011) developed the validation of UV 
Spectrophotometric Methods for estimation of dexibuprofen in bulk and dosage form. 
Measurement of absorption at maximum wavelength in phosphate buffer pH 6.8 was 
found to be at 221 nm by using 5% methanol. Beers law was obeyed in concentration 
range 0-60 µg/ml having line equation y = 0.046x +0.017 with r
2
 = 0.999. 
2.5  XIE Bin,et al
9
,(2008) Determination of dexibuprofen and its related substances 
in Dispersible Tablets by HPLC. Methods ODS-C18 column was applied and  mobile 
phase was acetonitrile and potassium phosphate and detected at 263 nm. Results 
calibration curve was linear over the range of 4×10
-3  
~ 100×10
-3
g/lit (r = 1 ).The mean 
recovery rate of contents was 99.69 % with RSD as 0.92% (n=9). 
2.6 Chul Soon Yong,et al
10
,(2009) Enhanced oral bioavailability of Dexibuprofen by 
a novel solid Self-emulsifying drug delivery system(SEEDS).The solid SEEDS was 
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characterised by SEM,DSC and XRD studies.The liquid SEEDS was a system that 
consisted of dexibuprofen , labrasol,capryol 90 and labrafil. The particle size analysis 
revealed no difference in the  z-average particle diameter of the reconstituted emulsion 
between liquid and solid SEEDS.  
2.7  S.Agatonovic –Kustrin, et al11,(2000) Determination of enantiomeric 
composition of ibuprofen in solid mixtures of the two by DRIFT Spectroscopy. Sample 
mixtures were dispersed as a 5% (w/w) mix in KBr and spectra were measured. T he 
original spectra were sampled between 650.16 & 3999 cm
-1
. A working range of 1-100 % 
of the R(-) enantiomer present as an impurity in S(+) enantiomer was established with a 
minimum quantifiable level of 1.67 % and a limit of detection of 0.5 %.The average 
recovery values were 100.95 & 98.02 for R(-) & S(+) enantiomer. 
2.8  Xie Bin, et al 
12 
,(2008) Determination of dexibuprofen and its related substances 
in dexibuprofen sustained – release suppositories by HPLC. Hypersil ODS column with  
mobile phase acetonitrile and potassium dihydrogen phosphate was used and detected at 
264 nm. The linearity was 4~128 mg/lit. The average recovery was 99.9% with RSD 0.3 
%. 
2.9  WANG Wen-ging, et al 
13
 ,(2008) Content Determination of dexibuprofen in the 
gel Preparation by HPLC. Hypersil ODS2 column was used, Mobile phase was 
acetonitrile and water and detected at 263 nm, flows at a rate of 1.0 ml/min. Linearity was 
performed in the range of 25.1- 251.0 µg/ml(r = 0.999). The average recovery was 
101.6% (n =9). 
2.10 ByranGowramma, et al
14
, (2011) developed the validation of Direct 
chiral separation of Ibuprofen Enantiomers of sustained release dosage form. 
Enantiomeric separation was achieved on  Lux 5 cellulose 1 column as stationary phase 
and Mobile phase consisting of perchloric acid and acetonitrile (50 :50) at a flow rate of 
1.0 ml/min and  detected at 254 nm.  RT for (R) and (S) enantiomers were 6.3 and 10.4 
min. Linearity was performed in the range of 0.5-3.0µg/ml. 
2.11 Rao, et al
15
, (2011)developed the validation of an UPLC Method for rapid 
determination of Ibuprofen and Diphenhydramine citrate in the presence of impurities in 
combined dosage form. The  method was developed using C18 Column with mobile 
phase containing a gradient mixture of solvent A&B and monitored at 220 nm. The  linear 
                                                                                       REVIEW OF LITERATURE 
 
Department of Pharmaceutical Analysis Page 15 
 
in the  range of  0.20-6.00 & 0.084-1.14 µg/ml for Ibuprofen and Diphenhydramine 
citrate. LOD  were ranged from 0.200-0.320 and 0.084-0.099 µg/ml for Ibuprofen and 
Diphenhydramine citrate impurities. LOQ were ranged from 0.440-0.880 and 0.258-0.372 
µg/ml for Ibuprofen and Diphenhydramine citrate impurities. 
2.12 Sohan S. Chitlange, et al
16
,(2009) Reported stability indicating HPTLC method 
for analysis of dexibuprofen in bulk and dosage form. The separation was carried out 
using n-Hexane : ethylacetate: glacial acetic acid (7.5:2.5:0.2v/v/v).254 plate was used as 
stationary phase. 
2.13 Tao, et al
17
, (2009) determined dexibuprofen-β- cyclodextrin inclusion complex 
by HPLC. The sample was dissolved with 75% methyl alcohol and prepared by 
ultrasonication. The mobile phase was methyl alcohol – 0.2%, phosphoric acid solution 
(75:25) and detected at 220nm. The linearity range of dexibuprofen was 10.01~50.05 g/lit 
(r = 0.9999) . The average recovery was 98.91 % (RSD =1.38 %). 
2.14. MandalUttam,et al
18
, (2008)  developed Boiequivalence study of two 
formulations containing 400 mg Dexibuprofen in Healthy Indian Subjects. The 
concentration of dexibuprofen in plasma  was determined by a validated HPLC method 
with UV detection using carbamazepine as internal standard. The formulations were 
compared using the parameters AUC, Cmax, t max,. Both preparation were well tolerated 
with no reactions observed throughout the study. 
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3. DRUG PROFILE 
3.1. DEXIBUPROFEN: 
(2S)-2-[4-(2-methylpropyl)phenyl]propanoic acid 
Dexibuprofen is a non-steroidal anti-inflammatory drug. It is the dextrorotatory 
enantiomer of ibuprofen.Most ibuprofen formulations contain a racemic mixture of 
dexibuprofen [ (+)-ibuprofen] and (-) – ibuprofen. 
Structure: 
 
 
 
Molecular weight: 206.281 g/mol 
Molecular formula:C13H18O2 
Description: Dexibuprofen is a white, crystalline powder.  
Dosage form: Tablets. 
Dosage : 200 to 500 mg 
Solubility: Soluble in isopropyl alcohol, ethanol absolute, ethyl acetate, n-hexane. 
Indications : 
 Pain and inflammation associated with musculoskeletal, joint and soft tissue 
disorders. 
 Primary dysmenorrhea. 
Special Precautions: 
 History of bronchial asthma 
 renal or hepatic disorders 
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 bleeding disorders 
 CV disease 
 elderly 
 lactation 
Adverse Effects : 
 GI bleeding 
 Heartburn 
 epigastric pain 
 dyspepsia 
 peptic ulcer 
 nausea 
 vomiting 
 diaorrhea 
 jaundice 
 hepatitis 
 visual disturbances 
 depression 
Pharmacokinetics: 
Dexibuprofen is absorbed from the gastrointestinal tract and peak plasma 
concentrations occur about 1 to 2 hours after ingestion. Dexibuprofen is also absorbed 
on rectal use. There is some absorption after topical application to the skin. 
Dexibuprofen is 90 to 99% bound to plasma proteins and has a plasma half-life of 
about 2 hours. It is rapidly excreted in the urine mainly as metabolites and their 
conjugates. About 1% is excreted in urine as unchanged dexibuprofen and about 14% 
as conjugated dexibuprofen. There appears to be little if any distribution into breast 
milk. 
Mechanism of Action: Dexibuprofen is a NSAID. It acts by inhibition of cyclo- 
oxygenase, which is     involved in prostaglandin synthesis. 
Bioavailability : 49-73 % 
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Plasma protein :  90-99 % 
 Half Life :          1.8 - 2 hours 
 
3.2.IMPURITIES OF DEXIBUPROFEN: 
 2-(4-butylphenyl)propionic acid (Impurity -B) 
 
 
 
 
 
 
 
 2-(4-isobutyrylphenyl)propionic acid(Impurity-J) 
 
 
 
 
 
 4-Isobutylacetophenone(Impurity-E) 
 
 
 
 
                                                                                      DRUG PROFILE 
 
Department of Pharmaceutical Analysis Page 19 
 
 
 Ibuprofen Methylester 
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4. AIM AND PLAN OF WORK 
4.1. NEED FOR METHOD DEVELOPMENT 
The exhaustive literature survey revealed that none of the most recognized 
pharmacopoeias or any journals includes the  determination of related substances of 
Dexibuprofen. So it is felt essential to develop a liquid chromatographic procedure which 
will serve a reliable, accurate, sensitive, and stability indicating method for the 
simultaneous determination of related substances of Dexibuprofen from tablets. 
4.2. AIM OF THE STUDY 
To develop and validate stability indicating related substances analytical method for 
the Dexibuprofen tablets using HPLC. 
4.3. PLAN OF THE PRESENT STUDY 
Development and optimization of the proposed chromatographic conditions 
 Selection of wavelength. 
 Selection of initial separation condition. 
 Nature of stationary phase (column). 
 Nature of mobile phase (peak modifier, solvent strength, ratio and flow rate). 
Validation of the developed method using various parameters 
 Specificity. 
 Limit of detection and limit of quantitation. 
 Determination of relative retention factor. 
 Linearity and range. 
 Accuracy. 
 Precision. 
 Filter compatibility. 
 Solution stability 
 Robustness. 
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5. EXPERIMENTAL WORK 
Instruments used : 
 HPLC with UV/PDA detector [waters] 
 Analytical balance [Sartorious] 
 PH meter [Lab India] 
 Sonicator [BandelinSonorex Super] 
 
Chemicals used : 
 HPLC grade [Millpore] water 
 Orthophosphoric acid HPLC grade [Merck] 
 Methanol HPLC grade [Fisher Scientific] 
 Sodium Hydroxide [Merck] 
 Hydrogen peroxide [Fisher Scientific] 
 Hydrochloric acid [Merck] 
 Acetonitrile [Merck] 
 
Drug Sample : 
Dexibuprofen drug sample obtained from Shasun Chemicals, Puducherry. 
 
Initialization of the instrument: 
Initially, the column was placed on the instrument and switch on the instruments and    
washed with  methanol, isopropyl alcohol and then finally with  water for 30 min. Then 
the system was  made to run with the  mobilephase for 30 min . 
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5.1.TRAILS : 
5.1.1.TRAIL- I  
Preparation of mobile phase A 
Prepared a mixture of 500 ml of acetonitrile ,500 ml of Milli Q Water and 0.5 ml of 
ortho phosphoric acid . Mixed well and degassed. 
Preparation of mobile phase B 
Mixed 0.5 ml of ortho phosphoric acid in 1000 ml of acetonitrile and degassed. 
5.1.2.TRAIL-II 
Preparation of mobile phase A 
Prepared a mixture of 400 ml of acetonitrile ,600 ml of Milli Q Water and 1.0 ml of 
ortho phosphoric acid . Mixed well and degassed. 
Preparation of mobile phase B 
Mixed 1.0 ml  of ortho phosphoric acid in 1000 ml of acetonitrile and degassed. 
 
5.1.3.TRAIL-III 
Preparation of mobile phase A 
Prepared a mixture of 350 ml of acetonitrile ,650 ml of Milli Q Water and 0.5ml of 
ortho phosphoric acid . Mixed well and degassed. 
Preparation of mobile phase B 
Mixed 0.5 ml of ortho phosphoric acid in 1000 ml of acetonitrile and degassed. 
Hypersil ODS column was used as stationary phase . 
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5.1.4. TRAIL-IV 
Preparation of mobile phase A 
Prepared  a mixture of 350 ml of acetonitrile ,650 ml of Milli Q Water and 0.5ml of 
ortho phosphoric acid . Mixed well and degassed. 
Preparation of mobile phase B 
Mixed 0.5 ml of ortho phosphoric acid in 1000 ml of acetonitrile and degassed. Flow 
rate was 2.0 ml/min. 
 
 
5.2. FINALISED  CHROMATOGRAPHIC CONDITIONS  
 
 Column    :       Waters symmetry, C18( 150mm×4.6mm, 
5µm) 
 Wavelength                               :              214 nm 
 Flow rate                 :        2.0 mL/minute 
 Column temperature                :        Ambient 
 Injection volume                :         20 µl 
 Pump Mode       :           Gradient 
 Run time        :         75 minutes 
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Table 2: Gradient Program 
Time  (Minutes) Mobile phase A (%) Mobile phase B (%) 
0 100 0 
25 100 0 
55 15 85 
70 15 85 
75 100 0 
 
5.3. PREPARATION OF SOLUTION  
Mobile phase preparation  
Preparation of mobile phase A 
Prepared a mixture of 350 ml of acetonitrile, 650ml of Milli Q Water and 0.5ml of 
ortho phosphoric acid. Mixed well and degassed. 
Preparation of mobile phase B 
Mixed 0.5 ml of ortho phosphoric acid in 1000 ml of acetonitrile and degassed. 
Preparation of diluent 
“ Mobile phase A” as a diluent. 
Standard stock solution  
Weighed accurately and transferred about 25.0 mg of Dexibuprofen reference 
standard/ working standard into a 100 ml volumetric flask. Added about 50 ml of 
methanol and sonicated for about 10 minutes and made up to volume with       
methanol.(≈ 250.0 µg/ml of Dexibuprofen). 
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Standard solution 
Transferred 2.0 ml of standard stock solution into 100.0 ml volumetric flask and made 
up the volume with diluent  and mixed well. (≈ 5.0 µg/ml of Dexibuprofen)) 
Note : Standard solution stable for 48 hours at ambient condition (25 ºC  ). 
Impurity –B Stock Solution [ 2-(4- butyl phenyl) propionic acid] 
Weighed accurately and transferred about 2.5 mg of Impurity –B[2-(4- butyl phenyl) 
propionic acid] standard and transferred  into a 25.0 ml volumetric flask, added about    
10 ml of methanol and sonicated for about 2 minutes and made up to volume with 
methanol and mixed well. (≈ 100.0 µg/ml of Impurity –B). 
Resolution solution 
Weighed accurately and transferred about 50.0 mg of Dexibuprofen reference 
standard/ working standard into a 25.0 ml volumetric flask. Added about 10 ml of 
methanol and sonicated for about 10 minutes to dissolved the material. To this added 1.0 
ml of the impurity stock solution and made up to volume with methanol and mixed.        
(≈ 2000.0 µg/ml of Dexibuprofen and ≈ 4.0 µg/ml of impurity-B ). 
Sample solution 
Determined the average weight of 20 tablets, Crushed the tablets to fine powder using 
mortar and pestle. Accurately weighed and transferred the sample powder equivalent to 
about 200 mg of Dexibuprofen into a 100 ml volumetric flask. Added about 10 ml of 
methanol and sonicated for about 10 minutes and made up the volume with diluent. 
Filtered the solution through 0.45µm nylon syringe filter and discarded first 5 ml of the 
filtrate. .  (≈ 2000.0 µg/mL of Dexibuprofen ) 
Note: Filtered sample solution stable for 48 hours at ambient condition (25 ºC). 
Procedure 
Separately injected each 20 µL of blank (diluent), standard solution (6 replicates) and 
sample solution into the chromatograph, recorded the chromatograms and measured the 
peak response for all peaks. Disregarded any peak corresponding to the blank. 
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Note: After every six sample injections, inject the blank, standard solution  as  
Bracketing      standard. 
 
Table-3: The relative retention time and correction factor of known impurities  
S.NO Name RRT RRF 
1 2(4-isobutyryl phenyl) propionic acid 
(Impurity : J) 
0.20 0.92 
2 2(4-butylphenyl) propionic acid 
(Impurity :B) 
1.04 0.91 
3 4-Isobutylacetophenone 
(4-IBAP) (Impurity-E) 
1.09 1.37 
4 Ibuprofen methyl ester  1.34 0.90 
5 Dexibuprofen 1.00 - 
 
 
 
5.4. EVALUATION OF SYSTEM SUITABILITY 
 Relative standard deviation for six replicate injections of standard area should be 
not more than 10.0%.   
 Resolution between Dexibuprofen and Impurity –B[2-(4- butyl phenyl) propionic 
acid ] peaks is not less than 1.5 in resolution solution . 
 Theoretical plate count for  Dexibuprofen should not be less than 5000. 
 
                                                                     EXPERIMENTAL WORK 
 
Department of Pharmaceutical Analysis Page 27 
 
 
5.5. CALCULATIONS 
For Known Impurity  
 
AT1 
x 
SD 
x 
2 
X 
100 
X 
Avg.Wt 
x 
P 
x 100 x 
1 
AD 100 100 TW LC 100 RRF 
  
For Unknown Impurity  
AT2 
x 
SD 
x 
2 
x 
100 
X 
Avg.Wt 
x 
P 
x 100 
AD 100 100 TW LC 100 
 
Where, 
AT1:   Area of any known impurity peak in the chromatogram of  sample solution 
AT2:  Area of unknown impurity peak in the chromatogram of  sample solution. 
AD:  Average peak area of Dexibuprofen in the chromatogram of standard solution. 
SD:  Weight of Dexibuprofen reference standard/working standard in mg. 
TW:  Weight of Dexibuprofen tablets powder sample taken in mg. 
Avg.Wt:  Average weight per tablet in mg. 
P: % Purity of Dexibuprofen reference standard/working standard (as is basis) 
LC:  Label claim of Dexibuprofen tablets   in mg. 
RRF:  Relative Response factor 
Total impurities: Sum of Known and Unknown impurities 
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6.1.ANALYTICAL METHOD DEVELOPMENT 
TRAIL-1 
Dexibuprofen and impurities :  
    System suitability results 
1.) Theoretical plates obtained from trail-1 were 1872 and 2748. 
2.) Resolution obtained from trail-1 was 0.7. 
3.)% RSD obtained from trail -1 was 17.3 and 22.7. 
 
TRAIL-2 
Dexibuprofen and impurities:  
    System suitability results 
1.) Theoretical plates obtained from trail-2 were 3327 and 1482. 
2.) Resolution obtained from trail-2 was 0.3. 
3.)% RSD obtained from trail -2was 18.6 and 21.3. 
 
   TRAIL-3 
Dexibuprofen and impurities:  
     System suitability results 
1.) Theoretical plates obtained from trail-3 were 3228 and 1985. 
2.) Resolution obtained from trail-3 was 0.45. 
3.) % RSD obtained from trail -3 was 14.9 and 21.2. 
     
TRAIL-4 
Dexibuprofen and impurities:  
    System suitability results 
1.) Theoretical plates obtained from trail-4 were 87652. 
2.) Resolution obtained from trail-4 was 2.8. 
3.) % RSD obtained from trail -4 was 0.5. 
 
TRAILS  DISCUSSION 
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     On evaluation of the above results, it can be concluded that trail 1, 2, 3 shows poor resolution 
 and affected the method significantly. Trail -4 shows good system suitability results and   also  
in the limit so the trail 4 were accepted and trail 1, 2, 3 were rejected. 
 
6.2. ANALYTICAL METHOD VALIDATION 
Method validation is the process of demonstrating the analytical procedures are suitable 
for their intended use and that they support the identity, strength, quality, purity and potency 
of drug substances and drug products. 
 
 
Purpose of Method Validation 
 
 Identification of sources and quantitation of potential errors. 
 
 Determination if method is acceptable for intended use 
. 
 Establish proof that a method can be used for decision making. 
 
 Satisfy regulatory requirements. 
       
 
 
 
 
Table-4: Specification of Impurities  
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Impurities Specification limit (%) 
Impurity J 0.20 
Impurity B 0.20 
Impurity E 0.20 
Methyl ester 0.30 
Any other impurity 0.17 
Total impurities  0.80 
 
 
Preparation of sample composite for validation  
Weighed 20 tablets and calculated the average weight of a tablet. Transferred the tablets 
into a mortar; crushed the tablets into fine powder. Use this powdered sample for validation. 
 
6.1. SYSTEM SUITABILITY   
 
     The system suitability of the method has been demonstrated as indicated by the tailing 
factor for Dexibuprofen, Resolution for Dexibuprofen and Impurity – B and the percentage 
RSD that is not more than 10.0 from six replicate injections of standard solution. The 
obtained results were shown in Table-5. 
 
 
 
 
Table-5: System suitabilityResults 
S.No. Observed results Acceptance criteria 
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1 Dexibuprofen– 64460 
The theoretical plate for peak due to Dexibuprofen 
should be not less than 5000. 
2 Impurity – B - 2.7 
Resolution between Dexibuprofen and 2(4-
butylphenyl)propanoicacid peaks is not less than 1.5. 
3 
System precision 
Dexibuprofen Peak area 
Injection 
1 121407 
2 120231 
3 120096 
4 120580 
5 120293 
6 119487 
Average 120349 
% RSD 0.5 
 
 
 
 
6.2. PRECISION 
 
6.2.1. System precision 
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Procedure 
Six replicate injections of standard solution were injected. The mean and percentage 
relative standard deviation (%RSD) for peak areas of Dexibuprofen were calculated. 
 
Acceptance criteria 
       Percentage relative standard deviation (%RSD) for peak areas of Dexibuprofen was not 
more than   10.0. 
 
Results and discussion 
       The method has been determined to be precise as demonstrated by % RSD that was not 
more than 10.0 for the determinations of related substances of Dexibuprofen tablets. The 
obtained results were shown in  Table-6. 
 
 
 
 
 
 
                       
 
 
 
 
 
 
Table-6: System Precision data 
Injection No. Peak area 
1 121407 
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2 120231 
3 120096 
4 120580 
5 120293 
6 119487 
Mean 120349 
Percentage relative standard 
deviation (%RSD) 
0.5 
 
 
 
6.2.2. Method precision 
   Prepare adequate quantity of mobile phase required for the continuation of mobile phase 
stability, standard and sample solution stability along with method precision and filter 
validation tests. These tests should be preferably continued in the same HPLC instrument. If 
different HPLC instrument is used run the required system suitability as appropriate. 
 
 
 
 
Impurities spiked sample solution 
Weighed accurately and transferred about 420.0 mg of powdered sample (equivalent to 
200 mg of Dexibuprofen) into a 100 ml volumetric flask. Added 50 ml of diluent, and 
sonicated for 10 minutes, cooled to room temperature and added each 5.0 ml of  impurity 
stock solutions and diluted to the volume with diluent. Mixed well and filtered through 0.45 
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µm nylon filter. Discarded first 5 ml of the filtrate. (≈ 2000 µg/ml of Dexibuprofen, ≈ 4.0 
µg/ml of impurity J,B&C ).   
 
 
Note:(i)Prepared  six replicate sample solutions using the same procedure. 
   (ii)  Allocated  spiked sample solution 1 for filter validation. 
   (iii) Allocated  standard and spiked sample solution for solution stability study. 
 
Procedure 
Separately injected the blank (diluent), standard solution (6 replicates), each impurities 
spiked sample solution, blank (diluent) and standard solution (bracketing) into the 
chromatograph and recorded the peak response. 
 
 
Calculation: 
For known impurity : 
 
AT1 
x 
SD 
x 
2 
X 
100 
X 
Avg.Wt 
x 
P 
x 100 x 
1 
AD 100 100 TW LC 100 RRF 
 
 
 
 
For Unknown Impurity : 
 
AT2 
x 
SD 
x 
2 
x 
100 
X 
Avg.Wt 
x 
P 
x 100 
AD 100 100 TW LC 100 
 
 
Where, 
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                 AT1:   Area of any known impurity peak in the chromatogram of  sample solution 
                 AT2:  Area of unknown impurity peak in the chromatogram of  sample solution. 
AD:  Average peak area of Dexibuprofen in the chromatogram of standard 
solution. 
SD:    Weight of Dexibuprofen reference standard/working standard in mg. 
TW:      Weight of Dexibuprofen tablets powder sample taken in mg. 
Avg.Wt:  Average weight per tablet in mg. 
P:        % Purity of Dexibuprofen reference standard/working standard (as is 
basis) 
LC:       Label claim of Dexibuprofen tablets in mg. 
RRF:   Relative Response factor 
 
Total impurities: Sum of Known and  Unknown impurities 
 
Acceptance criteria 
The percentage RSD of each individual known impurity and total impurities from six 
impurities spiked samples should be not more than 10.0. 
 
Results and Discussion 
    The method has been determined to be precise as demonstrated by % RSD that is not more 
than 10.0 for individual known impurity and total impurities from six determinations of 
impurities spiked samples at specification level. The obtained results were shown in Table-7.  
 
 
Table-7:  Method precision data 
Sample 
No.       
Percentage (w/w) 
Impurity-J Impurity-B Impurity -E Methyl ester Total 
impurities 
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6.2.3. Intermediate Precision (Ruggedness ) 
   Demonstrate the intermediate precision by performing the impurities spiked sample 
solution described under the method precision using different instrument, different column 
and second analyst on different day. 
Note: Prepared six replicate impurities spiked sample solutions as per method precision 
parameter. 
 
Procedure 
Separately injected the blank (diluent), standard solution (6 replicates), each impurities 
spiked sample solution, blank (diluent) and standard solution (bracketing) into the 
chromatograph and recorded the peak response. 
1 0.198 0.178 0.191 0.372 0.974 
2 0.194 0.179 0.190 0.350 0.945 
3 0.189 0.180 0.189 0.350 0.939 
4 0.194 0.185 0.194 0.358 0.958 
5 0.189 0.177 0.191 0.351 0.937 
6 0.189 0.182 0.191 0.350 0.941 
Avg. 0.192 0.180 0.191 0.355 0.949 
% RSD 0.0 2.3 0.0 0.0 1.2 
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Calculation 
For known, unknown and total impurities refer method precision parameter. 
 
Acceptance criteria 
 The percentage RSD of each individual known impurity and total impurities from 
six impurities spiked samples should be not more than 10.0. 
 The % RSD of both the analysts of impurities spiked samples for each individual 
known      impurity and total impurities should be not more than 10.0. 
 
 
Results and Discussion 
The method has been determined to be repeatable and precise as demonstrated by 
an RSD that was not more than 10.0 of individual known impurity and total impurities 
respectively from six impurities spiked samples at specification level of individual 
and combined results of both the analysts. The obtained results were shown in Table-
8. 
 
 
Table-8:Intermediate precision data 
Spl. No. 
Percentage (w/w) 
Impurity-J Impurity-B Impurity-E Methyl ester Total 
Analyst Analyst Analyst Analyst Analyst 
1 2 1 2 1 2 1 2 1 2 
1 0.24 0.22 0.22 0.21 0.16 0.14 0.14 0.15 0.86 0.83 
2 0.24 0.22 0.22 0.21 0.16 0.14 0.14 0.15 0.87 0.86 
3 0.24 0.22 0.22 0.21 0.16 0.14 0.14 0.16 0.88 0.87 
4 0.24 0.22 0.22 0.21 0.16 0.14 0.14 0.15 0.88 0.87 
5 0.24 0.22 0.23 0.22 0.16 0.14 0.14 0.16 0.89 0.88 
6 0.24 0.22 0.23 0.23 0.16 0.14 0.14 0.15 0.88 0.88 
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Avg. 0.24 0.22 0.22 0.22 0.16 0.14 0.14 0.15 0.9 0.9 
RSD 0.0 0.0 2.3 3.9 0.0 0.0 0.0 3.4 1.2 2.2 
RSD (12 
result) 
4.5 3.6 7.0 5.3 1.7 
*Analyst 1 data taken from method precision 
 
 
6.3. SPECIFICITY 
6.3.1. Interference from blank, placebo & impurities 
Placebo solution 
Weighed accurately and transferred equivalent to 200 mg of Dexibuprofen (subtracted the 
200 mg from the obtained equivalent weight) into a 100 ml volumetric flask. Added about 50 
ml of diluent, sonicated for 10 minutes, cooled to room temperature and diluted to the volume 
with diluent. Mixed well and filtered through 0.45 µm nylon membrane filter, discarded first 
5 ml of the filtrate. 
 
Resolution standard: 
Weighed accurately and transferred  about 50.0 mg of Dexibuprofen working reference 
standard into 25 ml volumetric flask, added  about 10ml of methanol and sonicated for 10 
minutes, cooled  to room temperature and added 1 ml of impurity B Stock solution and 
diluted to the volume with diluent. Mixed well and filtered through 0.45 µm nylon membrane 
filter, discarded first 5 ml of the filtrate. 
 
Impurities spiked sample solution (at specification level) 
Weighed accurately and transferred about 420.0 mg of powdered sample (equivalent to 
200 mg of Dexibuprofen) into a 100 ml volumetric flask. Added 50 ml of diluent, and 
solicited for 10 minutes, cooled to room temperature and added each 5.0 ml of impurity stock 
solutions and diluted to the volume with diluent. Mixed well and filtered through 0.45 µm 
nylon filter. Discarded first 5 mL of the filtrate. (≈ 2000 µg/ml of Dexibuprofen, ≈ 4.0 µg/ml 
of impurity J,B&C). 
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  6.3.2. Interference from forced degradation study 
S.No. 
Forced degradation 
study 
Volume and strength of reagent 
1 Acid hydrolysis 10 mlof 5 N Hydrochloric acid 
2 Alkali hydrolysis 10 ml of 5 N Sodium hydroxide 
3 Peroxide oxidation 10 mlof 30 % Hydrogen peroxide 
 
 
Placebo Procedure for acid, alkali, Peroxide oxidation 
Weighed accurately and transferred about 220.0 mg of placebo into 3 separate 100 ml 
volumetric flask, added 50 ml of diluent and sonicated to dissolve the content. To the first 
100 ml flask, added 10 ml of 5N HCL. Added 10 ml of 5N NaOH into second and added 10 
ml of 30% Hydrogen peroxide into third 100ml flask, kept on water bath / reflux for 12 
hours. Cooled and diluted to the volume with diluent and mixed well. Filtered through 0.45 
µm nylon filter, discarded first 5 ml of the filtrate and collected the filtrate. 
 
Sample Procedure for acid, alkali, peroxide oxidation 
Weighed accurately and transferred about 420.0 mg of Dexibuprofen into 3 separate 100 
ml volumetric flask, added 50 ml of diluent and sonicated to dissolve the content. To the first 
100 ml flask, added 10 ml of 5N HCL. Added 10 ml of 5N NaOH into second and added 10 
ml of 30% Hydrogen peroxide into third 100ml flask, kept on water bath / refluxed for 12 
hours. Cooled and diluted to the volume with diluent and mixed well. Filtered through 0.45 
µm nylon filter, discarded first 5 ml of the filtrate and collected the filtrate. 
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Note: After heating/ refluxion, neutralized the solution with sodium hydroxide and 
hydrochloric acid solution in acid and alkali hydrolysis respectively .(Check and adjust the 
pH, if required, in the range of about 5  to 7). 
 
  Procedure for thermal and photo degradation 
Spread evenly about 1 g of placebo, Dexibuprofen powdered sample in separate glass 
petridish for each degradation condition and exposed as per the following condition. 
                               
 
 
 
 
 
 
 
 Table: 9 Thermal and photo degradation 
 
S.No. Sample degradation Stressing condition Hours to be exposed 
1 
Thermal 
( oven) 
105° C 24 
2 Photo 
Controlled (covered with 
aluminum foil)  
1.2 million lux 
Uncontrolled (direct 
exposure) 
 
Thermal and photo light condition: 
Sample preparation 
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Sample was kept in an oven at 105° C for about 24 hours for thermal condition and 
Sample was exposed to light of 1.2 million lux hours for photo light condition. Weighed 
accurately and transferred about 420.0 mg of Dexibuprofen into a separate 100 ml volumetric 
flask, added 50 ml of diluent and sonicated for 10 minutes to dissolve the content. Cool and 
dilute to the volume with diluent and mix well. Filtered through 0.45 µm nylon filter, 
discarded first 5 ml of the filtrate and collected the filtrate. 
Placebo Preparation 
Weighed accurately and transferred about 220.0 mg of Placebo into a separate 100 ml 
volumetric flask and followed the same procedure as mention above  for  sample. 
 
6.3.3. Evaluation of the sample chromatograms 
The degradation of analyte peaks shall be in the range of 5 to 30 % by area normalization 
method. If the degradation level is higher than 30 %, stress condition can be altered (less 
concentration or less volume of stressing agent or reduced heating/refluxing period) in acid, 
alkali, water hydrolysis and peroxide oxidation. For other degradation, report the obtained 
degradation level as highest stress condition. 
Ascertain the peak purity, with the help of software; for each individual peak(preferably 
peak height of the analyte should be less than 1.0 AU at the highest absorbance) in the 
chromatogram. If required, adjust the test solution concentration accordingly to achieve the 
desired peak height. If the main peak is not degraded in highest stress condition, then 
conclude the sample is stable in that particular condition. 
Procedure 
Separately injected blank (diluent), standard solution (6 replicates), blank (diluent), 
placebo solution, each individual impurity identification solution, impurities spiked sample 
solution, blank (diluent), each stressed placebo solution, unstressed sample solution, each 
stressed sample solution, blank (diluent), standard solution  ( bracketing) into the 
chromatograph and recorded the peak response. 
 
Acceptance criteria 
 The analyte peaks (impurity peaks and main peak) should be separated from placebo 
peaks, blank peaks and from each other. 
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 Peak purity of known impurities and main peaks in standard solution, sample solution, 
each impurity identification solution and impurities spiked sample solution should 
pass (purity angle should be less than purity threshold). Report the peak purity values. 
 Report the relative retention time of known impurities with respect to Dexibuprofen 
peak from impurities spiked sample solution. 
 Major degradation peaks should be separated from the analyte peaks in stressed 
sample. 
 Peak purity should pass for Dexibuprofen peak. Report the peak purity value of 
known impurity peaks,Dexibuprofen peak from each stressed sample. 
 
 
6.3.5. Results and Discussion 
The method was found to be specific as demonstrated by forced degradation studies  that 
all degradation impurities were resolved from the analyte peaks, no interference was 
observed from the placebo and diluent with respected to Dexibuprofen and related impurities.  
 
In addition, Photo diode array detector (PDA) was used to demonstrate the peak spectral 
homogeneity with the aid of peak purity results. The related substances method has been 
demonstrated as suitable for monitoring the long term stability of Dexibuprofen tablets. The 
obtained results were shown in Table-10 to 13 
 
Table-10: Placebo interference data 
Sample Name Interference 
Peak found 
(Yes/No) 
Acceptance criteria 
Blank No Placebo solution should not show 
any peak at the retention time of 
known impurity peak and also 
peak due to Dexibuprofen 
Unstressed placebo No 
Acid hydrolysed placebo No 
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Alkali hydrolysed placebo No 
Peroxide oxidised placebo No 
Thermal stressed placebo No 
Photo stressed placebo No 
 
 
Table-11: Relative Retention Time of impurities from impurities spiked sample 
S.No. Name of the impurity Relative retention time 
1 Impurity-J 0.20 
2 Impurity-B 1.04 
3 Impurity-E 1.09 
4 Methyl ester 1.34 
 
       
 
Table-12: Peak purity data of impurities spiked sample 
S.No Peak Name 
Retention 
time 
Purity 
angle 
Purity 
threshold 
Purity flag 
1 Impurity-J 6.113 2.129 7.605 No 
2 Dexibuprofen 30.779 0.211 6.097 No 
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Table-13: Peak purity data of  Dexibuprofen from forced degradation studies 
S.No Condition % Purity Purity 
angle  
Purity 
Threshold 
Purity 
Flag 
1 Unstressed Sample 99.98 0.437 0.625 No 
2 Acid stressed Sample 99.97 0.516 0.701 No 
3 Alkali stressed Sample 99.97 0.384 0.606 No 
4 Peroxide stressed Sample 99.95 0.419 0.633 No 
5 Heat stressed Sample 97.78 0.454 0.669 No 
6 Photo light stressed 
Sample-Controlled 
condition 
99.98 0.366 0.578 No 
7 Photo light treated Sample-
Uncontrolled condition 
99.98 0.349 0.565 No 
 
 
3 Impurity-B 32.075 2.779 9.564 No 
4 Impurity-E 33.463 0.998 7.191 No 
5 Methyl ester 41.285 1.605 8.225 No 
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6.4. DETERMINATION OF LIMIT OF DETECTION AND LIMIT OF 
QUANTITATION 
 
Determine the limit of detection (LOD) and limit of quantitation (LOQ) for all specified 
impurities, Dexibuprofen based on signal to noise ratio method. 
Procedure:  
Separately injected the blank (diluent), standard solution (6 replicates), blank (diluent) (2 
replicates), each LOD & LOQ test solution (from lowest to highest concentration) into the 
chromatograph and recorded the peak response. 
 
LOD & LOQ calculation 
The limit of detection and (LOD) and limit of quantification (LOQ) was determined by 
signal to noise ratio method by using the formula.  
 
Signal to noise ratio (S/N) =2H/h 
H – Height of the analyte peak 
 h- Height of the noise 
 
LOD and LOQ value was verified by giving six replicate injections of solution containing 
impurities and Dexibuprofen at this level. The percentage relative standard deviation (%RSD) 
calculated for the peak areas and tabulated in table 14. 
 
Results and Discussion of LOD & LOQ 
The LOD and LOQ of known impurities, Dexibuprofen has been determined by signal to 
noise.The obtained results were shown in Table-14 
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Table-14:  Results for LOD and LOQ 
Name of the 
compound 
Limit of Detection Limit of Quantification 
S/N % S/N % 
Impurity J 6 0.004 21 0.01 
Dexibuprofen 5 0.004 17 0.01 
Impurity B 3 0.004 13 0.01 
Impurity E 4 0.002 22 0.005 
Methyl ester 8 0.004 18 0.01 
 
 
 
6.5. LINEARITY  
 
The linearity of response of known impurities and Dexibuprofen should be established 
over a range of concentrations between LOQ level to 150 % of specification limit. 
 
Linearity stock solution1 : 
Weighed accurately and transferred about 10.0 mg of Dexibuprofen reference 
standard/working standard  into a 25 ml volumetric flask, dissolved and dilute to the volume 
with acetonitrile and mixed well. (≈ 400.0 µg/ml). (same procedure for Impurity-J,B,&E, 
Methyl ester). 
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LOQ Level  :( For Dexibuprofen, Impurity –J,B& Methyl ester ) 
Pipetted 1 ml from stock solution I to 100 ml volumetric flask, dissolved and diluted to 
the volume with diluent and mixed well. Transferred 1 ml of this solution to 20 ml volumetric 
flask and made up with diluent (0.2 µg/ml). 
For Impurity E: 
Pipetted 1 ml from stock solution I to 100 ml volumetric flask, dissolved and diluted to 
the volume with diluent and mixed well. Transferred 0.5 ml of this solution to 20 ml 
volumetric flask and made up with diluent (0.1 µg/ml). 
 
Stock solution II: 
Pipetted 5 ml from stock solution I to  50 volumetric flask, dissolved and diluted to the 
volume with diluent and mixed well.  
 
 
Stock solution III : 
Pipetted 5 ml from stock solution I (Methyl ester) to  100 ml volumetric flask, dissolved 
and diluted to the volume with diluent and mixed well.  
 
25 % Level : :( For Dexibuprofen, Impurity –J,B& E) 
Transferred 0.5 ml of stock solution II to 20 ml volumetric flask and made up with diluent 
(1.0 µg/ml). For Methyl ester: Transferred 1.5 ml of stock solution III to 20 ml volumetric 
flask and made up with diluent (1.5 µg/ml). 
 
50 % Level : :( For Dexibuprofen, Impurity –J,B& E) 
Transferred 1.0 ml of stock  solution II to 20 ml volumetric flask and made up with 
diluent (2.0 µg/ml). For Methyl ester: Transferred 3.0 ml of stock solution III to 20 ml 
volumetric flask and made up with diluent (3.0 µg/ml). 
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75%Level : :( For Dexibuprofen, Impurity –J,B& E) 
Transferred 1.5 ml of stock  solution II to 20 ml volumetric flask and made up with 
diluent(3.0 µg/ml). For Methyl ester: Transferred 4.5 ml of stock solution III to 20 ml 
volumetric flask and made up with diluent (4.5 µg/ml). 
 
100 % Level : ( For Dexibuprofen, Impurity –J,B& E) 
Transferred 2.0 ml of stock  solution II to 20 ml volumetric flask and made up with 
diluent (4.0 µg/ml). For Methyl ester: Transferred 6.0 ml of stock solution III to 20 ml 
volumetric flask and made up with diluent       (6.0 µg/ml). 
 
125 % Level : :( For Dexibuprofen, Impurity –J,B& E) 
Transferred 2.5 ml of stock  solution II to 20 ml volumetric flask and made up with 
diluent (5.0 µg/ml). For Methyl ester: Transferred 7.5 ml of stock solution III to 20 ml 
volumetric flask and made up with diluent (7.5 µg/ml). 
 
150 % Level : :( For Dexibuprofen, Impurity –J,B& E) 
Transferred 3.0 ml of stock  solution II to 20 ml volumetric flask and made up with 
diluent (6.0 µg/ml). For Methyl ester: Transferred 9.0 ml of stock solution III to 20 ml 
volumetric flask and made up with diluent (9.0 µg/ml). 
 
Linearity test solutions 
Prepared individual linearity solutions from linearity stock solution according to the table 
below. 
Procedure 
Separately injected the blank (diluent), standard solution (6 replicates), blank (diluent) (2 
replicates) and each linearity solution (from lowest to highest concentration) into the 
chromatograph and recorded the peak response. 
 
 
Linearity calculation 
                                                          RESULTS AND DISCUSSION                                                                       
 
Department of Pharmaceutical Analysis Page 49 
 
Plot the respective peak area obtained in each linearity solution against the concentration 
(in X-axis). Using suitable software, performed a linear regression analysis to generated a 
best-fit line. Determined the correlation coefficient (r) of the best-fit line. 
 
Calculation for RRF value for Dexibuprofen impurities 
 
                                 Slope of Impurity-J                    % Purity ofDexibuprofen 
 RRF   =         -------------------------------- X ---------------------------------------- 
                                 Slope of Dexibuprofen               % Purity of impurity-J 
 
  
Acceptance criteria 
 The correlation coefficient (r) value should be not less than 0.990 
 Report the slope, y-intercept and RRF value. 
 
Results and Discussion 
The method was found to be linear in the range of LOQ level to 150 % of specification 
limit of known impurities,Dexibuprofen indicated by a correlation coefficient that is ≥ 
0.990. The obtained results were shown in Table-15 to 19, figure-1 to 5. 
 
 
 
 
 
 
 
 
 
Table-15: Linearity data of impurity -J 
S.No. % w.r.to specification limit Concentration (µg/ml) Peak Area 
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1 LOQ 0.1981 4282 
2 25% 0.9905 23551 
3 50% 1.9810 45954 
4 75% 2.9714 63758 
5 100% 3.9619 91132 
6 125% 4.9524 110112 
7 150% 5.9429              129388 
 
Figure-1: Linearity graph of  Impurity –J: 
 
 
 
 
 
Table-16: Linearity data of Dexibuprofen 
S.No. %w.r.to specification limit Concentration (µg/ml) Peak Area 
1 LOQ 0.2029 6247 
y = 22168x 
r² = 0.9978 
0 
20000 
40000 
60000 
80000 
100000 
120000 
140000 
0 1 2 3 4 5 6 7 
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2 25% 0.8542 24568 
3 50% 1.7084 43196 
4 75% 2.5625 64711 
5 100% 3.4167 86213 
6 125% 4.2709 104676 
7 150% 5.1251 123867 
 
 
 
                       Figure 2: Linearity graph of Dexibuprofen 
 
 
 
 
                Table 17: Linearity data of impurity-B 2(4-butylphenyl )propionic acid 
S.No. %w.r.to specification limit Concentration (µg/ml) Peak Area 
1 LOQ 0.1852 3790 
y = 21886x 
r² = 0.9991 
0 
20000 
40000 
60000 
80000 
100000 
120000 
140000 
0 1 2 3 4 5 6 
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2 25% 0.9261 21333 
3 50% 1.8521 42494 
4 75% 2.7782 59920 
5 100% 3.7043 82721 
6 125% 4.6303 100480 
7 150% 5.5564 120845 
 
Figure-3 : Linearity graph of Impurity-B 
 
 
 
 
 
                 Table- 18: Linearity data of Impurity E [4-Isobutylacetophenone] 
S.No. %w.r.to specification limit Concentration (µg/ml) Peak Area 
1 LOQ 0.0947 4175 
2 25% 0.9467 32793 
y = 21886x 
r² = 0.9991 
0 
20000 
40000 
60000 
80000 
100000 
120000 
140000 
0 1 2 3 4 5 6 
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3 50% 1.8934 65157 
4 75% 2.8401 92261 
5 100% 3.7868 128575 
6 125% 4.7335 157597 
7 150% 5.6802 18590 
 
 
Figure 4: Linearity graph of  Impurity –E 
 
 
 
 
 
                      Table-19: Linearity data of Ibuprofen methyl ester 
S.No. %w.r.to specification limit Concentration (µg/ml) Peak Area 
1 LOQ 0.1879 3006 
2 25 1.5660 31301 
y = 33171x 
r² = 0.9989 
0 
50000 
100000 
150000 
200000 
0 1 2 3 4 5 6 
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3 50 3.1320 62864 
4 75 4.6980 99877 
5 100 6.2640 126612 
6 125 7.8300 163729 
7 150 9.3960 201648 
 
  
 
                              Figure-5: Linearity graph of Methyl ester 
 
 
 
                   Table -20 – Slope, y-intercept & Co-efficient of correlation  
Compound Name  Slope Y-Intercept 
Coefficient of 
correlation (r) 
Impurity J 21863 1298 1.000 
Dexibuprofen 23842 2995 1.000 
y = 20992x 
r² = 0.9981 
0 
50000 
100000 
150000 
200000 
250000 
0 2 4 6 8 10 
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Impurity B 21654 922 1.000 
Impurity E 32724 1827 1.000 
Ibuprofen methyl 
ester 
21364 -2506 1.000 
 
 
                     Table-21: Summary of RRF values 
Name of the compound RRF 
Impurity J 0.92 
Dexibuprofen - 
Impurity B 0.91 
Impurity E 1.37 
Ibuprofen methyl ester 0.90 
 
 
 
6.6. ACCURACY 
 
Preparation of Sample solution (unspiked) 
Weighed and crushed 20 tablets by using mortar and pestle. Accurately weighed and 
transferred about 420.0 mg of powdered sample (equivalent to 200 mg of Dexibuprofen) into 
a 100 ml volumetric flask. Added 50 ml of diluent, and sonicated for 10 minutes, cooled to 
room temperature and diluted to the volume with diluent. Mixed well and filtered through 
0.45 µm nylon filter. (≈ 2000 µg/ml of Dexibuprofen). 
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Preparation of spiked solution : 
Stock Solution: 
Weighed accurately and transferred about 10.0 mg of impurity   into a 25 ml volumetric 
flask, dissolved and diluted to the volume with diluent and mixed well. (same procedure for 
all impurities and dexibuprofen ). 
 
LOQ LEVEL : 
For impurity J,B,Methyl ester, Dexibuprofen : 
Transferred 1 ml of stock solution to 100 ml volumetric flask and made up with diluent. 
Pipetted 5.0 ml of this solution to 100 ml volumetric flask and made up with diluent.  (0.2 
µg/ml). 
 
For Impurity E : 
Transferred 1 ml of stock solution to 100 ml volumetric flask and made up with 
diluent. Pipetted 2.5 ml of this solution to 100 ml volumetric flask and made up with 
diluent.(0.1 µg/ml). 
 
 
 
 
100 % LEVEL : 
For impurity J, B, E, Dexibuprofen: 
Transferred 10 ml of stock solution to 50 ml volumetric flask and made up with diluent. 
Pipetted 5.0 ml of this  solution  to 100 ml volumetric flask and made up with diluent (4.0 
µg/ml). 
For Methyl ester : 
Transferred 15 ml of stock solution to 50 ml volumetric flask and made up with diluent. 
Pipetted 5.0 ml of this  solution  to 100 ml volumetric flask and made up with diluent (6.0 
µg/ml). 
 
150 % LEVEL : 
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For impurity J,B,E, Dexibuprofen: 
Transferred 10 ml of stock solution to 20 ml volumetric flask and made up with diluent. 
Pipetted 3.0 ml of this  solution  to 100 ml volumetric flask and made up with diluent(6.0 
µg/mL). 
For Methyl ester : 
Transferred 15 ml of stock solution to 20 ml volumetric flask and made up with diluent. 
Pipetted 3.0 ml of this  solution  to 100 ml volumetric flask and made up with diluent (9.0 
µg/ml). 
Procedure 
6.6.1. Accuracy for known impurities 
Preparation of accuracy sample solutions (spiked) 
Weighed accurately and transferred about 420.0 mg of powdered sample (equivalent to 
200mg of Dexibuprofen) into a 100 ml volumetric flask. Added 50 ml of diluent and spiked 
the specified volume of each impurity stock solution to the same flask, sonicated for 10 
minutes, cooled to room temperature and diluted to volume with diluent. Mixed well and 
filtered the solution through 0.45 µm nylon membrane filter and discarded first 5 ml of the 
filtrate. 
Note: Prepared three accuracy samples for each level. 
Procedure 
Separately injected the blank (diluent), accuracy standard solution (6 replicates), sample 
solution (unspiked), blank (diluent), each accuracy solution for known impurities (from 
lowest to highest concentration), blank (diluent), each accuracy solution for unknown 
impurities (from lowest to highest concentration), blank (diluent) and standard solution 
(bracketing) into the chromatograph and record the peak response. 
 
    Amount recovered in µg 
 Percentage recovery   = ---------------------------------- X 100 
                                   Amount added in µg 
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Acceptance criteria 
 
 The percentage recovery of known impurity, Dexibuprofen at each level 
concentration should be between 90.0 and 110.0. 
 The % RSD of percentage recovery should be not more than 10.0 at each level. 
 
Results and Discussion 
The method has been determined to be accurate in the range of LOQ level to about 150 % 
level of specification limit, as demonstrated by the recovery of known impurities, 
Dexibuprofen at each level concentration should be between 90.0 and 110.0.Percentage RSD 
that is not more than 10.0 for triplicate results at each level. The obtained results were shown 
in Table-22. 
 
 
 
Table-22: Accuracy data of Impurity-J, Dexibuprofen & Impurity-B, Impurity-E, Methyl 
ester 
Level Imp-J Dexibuprofen Imp-B Imp-E Methyl ester 
 Recovery RSD Recovery RSD Recovery RSD Recovery RSD Recovery RSD 
LOQ 101.9 2.2 99.9 0.6 95.1 2.4 103.0 1.1 97.9 3.6 
100 100.3 0.2 103.7 2.1 97.0 0.5 101.0 1.0 101.2 0.2 
150 100.4 0.5 101.7 0.4 97.9 0.1 101.8 0.1 101.4 0.2 
 
 
 
 
6.7. RANGE 
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Derive the method range from linearity study. The linear range of analytical method was 
demonstrated with suitable level of accuracy and precision in the respective parameters. 
 
Results and Discussion: 
  The method range has been derived from linearity study that is LOQ level to 150% level of 
specification concentration and demonstrated with suitable level of precision and accuracy . 
 
6.8. STANDARD AND SAMPLE SOLUTION STABILITY 
 
The standard and sample solution stability can be evaluated by injecting the standard 
solution and impurities spiked sample solution obtained from method precision at appropriate 
time intervals up to 48 hours of the respective solutions stored in sample compartment of 
HPLC instrument at 25
◦
C  (ambient ) conditions. 
 
 
 
Procedure 
Separately injected the blank. (diluent) and each solution stability standard and sample 
solutions into the chromatograph and recorded the peak response. 
 
Calculation 
For known, unknown and total impurities refer method precision parameter. 
 
Acceptance criteria 
 The cumulative percentage RSD of peak area response due to Dexibuprofen from 
standard solution should be not more than 10.0. 
 The cumulative percentage RSD of each individual known impurity peak area in 
impurities spiked sample solution should be not more than 10.0. 
 The cumulative percentage RSD of total impurities from impurities spiked sample 
solution should be not more than 10.0. 
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Results and Discussion 
    The standard solution and impurities spiked sample solutions were monitored for stability 
up to 48 hours. The standard solution stable for 48 hours in ambient .As demonstrated by 
cumulative percentage RSD that was not more than 10.0 for peak area due to Dexibuprofen in 
standard and percentage of known,total impurities in spiked sample. The obtained results 
were shown in Table- 23&24. 
 
 
 
 
 
Table-23:  Solution stability data of standard solution 
Ambient condition : 
Time in 
hours 
Initial 5 8 12 16 24 32 40 48 
Cumulative 
% RSD 
- 0.9 1.2 1.0 0.9 0.9 0.9 0.9 0.9 
 
 
Table-24:  Solution stability data of impurities spiked Sample solution 
Time in 
hours 
Cumulative % RSD 
Impurity-J Impurity-B Impurity-E Methyl ester Total 
Initial - - - - - 
5 0.8 0.9 0.9 0.2 0.2 
8 0.8 0.9 0.6 0.3 0.3 
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12 0.7 0.9 0.5 0.2 0.3 
16 0.6 1.0 0.6 0.5 0.4 
24 0.8 0.9 0.6 0.6 0.4 
32 0.8 1.1 0.9 0.8 0.5 
40 1.0 1.1 1.2 1.1 0.7 
48 1.2 1.0 1.5 1.5 1.0 
6.9. FILTER VALIDATION 
 
Test Preparation: 
       Used the impurities spiked sample solution prepared in the method precision study; 
filtered a portion of the sample solution through 0.45 µm nylon filter, discarded first 5 ml of 
the filtrate and also centrifuged a portion of sample solution and collected the supernatant 
solution (unfiltered). 
Procedure:  
        Separately injected the blank (diluent), each filtered and unfiltered sample solution, 
blank (diluent) and standard solution (bracketing) into the chromatograph and recorded the 
peak response. 
 
Calculation:  
      For known, unknown and total impurities refer method precision parameter. Calculated 
the percentage difference of individual known impurity and total impurities between the 
filtered and unfiltered (centrifuged) impurities spiked sample solution.  
 
                            % result of unfiltered – % result of filtered 
 % Difference = -----------------------------------------------------  
                                       % result of unfiltered 
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Acceptance criteria: 
     The percentage difference between the unfiltered (centrifuged) and filtered sample for 
individual known impurity and total impurities should be not more than 10.0.  
Results and Discussion 
     The use of 0.45 µm nylon filters has been validated as indicated by percentage difference 
between the filtered and unfiltered samples that were not more than 10.0 for known and total 
impurities. The obtained results were shown in Table-25. 
 
                               Table-25: Filter validation data  
Name of Impurity 
Centrifuged Nylon filtered 
% w/w %w/w % Difference  
Impurity-J 0.184 0.186 1.1 
Impurity-B 0.223 0.225 0.9 
Impurity-C 0.243 0.244 0.4 
Methyl ester 0.353 0.354 0.3 
Total impurities 1.030 1.035 0.5 
 
 
6.10. ROBUSTNESS 
 
The robustness of the method shall be established by making deliberate minor variations 
in the following method parameters like, 
 
 Change in flow rate by ± 10 % of actual flow rate  
 Change in organic content in mobile phase ± 2% absolute. 
 Change in wavelength by ± 2 nm. 
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Method parameter 
Lowest altered 
condition 
Actual 
condition 
Highest altered 
condition 
Flow rate 
(mL/min) 
1.8 2.0 2.2 
Organic 
content(%) 
33 35 37 
Wavelength (nm) 212 214 216 
   
Procedure 
Separately injected the blank (diluent), standard solution (6 replicates) into the 
chromatograph and recorded the peak response. 
Note: Follow the same procedure for all altered method parameters and evaluated the 
acceptance criteria. If the acceptance criteria failed, narrow the method parameter and 
reported on range at which acceptance criteria passes. 
 
Acceptance criteria: It should meet the system suitability parameters. 
 
 
Results and Discussion 
    The robustness of the method was demonstrated by making deliberate changes in flow rate, 
organic content and wavelength as indicated by monitoring the tailing factor for 
Dexibuprofenis not more than 2.0 in standard solution. Percentage RSD of Dexibuprofen area 
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was not more than 10.0 from six replicate injections of standard solution. The obtained results 
were shown in Table-26-28. 
 
 
Table-26: Robustness data for flow rate variation 
Flow rate (mL/min) 
Minus flow 
(1.8) 
Plus flow 
(2.2) 
Theoretical plate count for peak due to 
Dexibuprofen 
88544 43603 
%RSD for peak due to Dexibuprofen 0.8 0.4 
Resolution  2.5 2.4 
 
 
 
                     Table- 27: Robustness study data for solvent variation 
Organic content 
Minus solvent 
(35) 
Plus solvent 
(37) 
Theoretical plate count for peak due to 
Dexibuprofen 
147541 9013 
%RSD for peak due to Dexibuprofen 1.1 1.6 
Resolution  2.4 2.9 
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                  Table-28: Robustness study data for wavelength variation 
  
Wavelength (nm) 
Minus wavelength 
(212 nm) 
Plus wavelength 
(216 nm) 
Theoretical plate count for peak due to 
Dexibuprofen 
65200 64054 
%RSD for peak due to Dexibuprofen 0.7 0.5 
Resolution 2.6 2.6 
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7. SUMMARY AND CONCLUSION 
SUMMARY: 
In this project, a high versatile HPLC was used for estimation of related substances 
of dexibuprofen in tablets. The separation was achieved by using Waters symmetry 
column with acetonitrile and ortho phosphoric acid as mobile phase. The retention time 
was 30.6 min for dexibuprofen at 214 nm. The system suitability parameters like 
Relative standard deviation, Resolution, Theoretical plate count were determined and 
found to be in acceptance limit. 
 
The overall results obtained were summarized in table – 29 
 
S.No. Parameters  Resolution % RSD Plate count 
1 System precision 2.7 0.5 64460 
2 Method precision 2.8 0.2 62243 
3 LOD and LOQ 2.6 0.4 68144 
4 Specificity 2.5 2.0 56686 
5 Linearity 2.5 0.9 62484 
6 Accuracy 2.6 1.5 62131 
7 Forced degradation 2.6 1.4 81612 
 
 
CONCLUSION : 
 
A stability study was carried out with an efficient HPLC method for the quantification 
of related substances of Dexibuprofen in tablets was developed and validated. The present 
study was validated as per the ICH guidelines. Validation experiments proved that the 
HPLC analytical method is linear in the range of 40 µg/ml  as well as accurate, precise 
(repeatability and intermediate precision levels) and specific, being able to separate the 
main drug from its degradation products. The proposed method was also found to be 
robust with respect to flow rate, column oven temperature and composition of mobile 
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phase. Due to these characteristics, the method has stability indicating properties being fit 
for its intended purpose, it may find application for the routine analysis of the related 
substances of Dexibuprofen in tablets. 
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8. CHROMATOGRAMS 
8.1. METHOD DEVELOPMENT 
Injection Volume: 20.00 µl,           Run Time: 75.0 Minutes 
Wavelength: 214 nm,   Flow-Rate :2.0 mL/min 
 
 Figure- 6                              Blank [Diluents] 
 
 
 
 
 
 
 
 Figure- 7                           Placebo Solution 
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                                   Figure – 8                         Standard Solution 
 
 
 
Standard solution data 
Peak  Results 
Name RT (min) Area (μV*sec) % Area 
Dexibuprofen 30.627 116358 100.00 
 
 
 
 
Figure – 9   Sample solution 
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Sample Solution Data 
Compound Name RT (min) Area (μV*sec) % Area 
Impurity –J 6.095 84160 0.19 
Dexibuprofen 30.738 44393567 98.91 
Impurity –B 32.078 74644 0.17 
Impurity –E 33.473 120949 0.27 
Methyl ester 41.264 154374 0.34 
 
8.2. SYSTEM SUITABILITY 
 
 Figure – 10                        System Suitability Solution 
 
Name Retention time Plate count 
Dexibuprofen 30.851 64460 
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8.3.SPECIFICITY 
 
8.3.1.IDENTIFICATION OF  IMPURITIES  
 
 Figure – 11                                   Impurity-J 
 
 
 
                                   Figure – 12                   Impurity-B 
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       Figure – 13                        Methyl ester 
 
 
 
 
Figure – 14    Impurity-E 
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Identification of  Impurities Data 
Sample Name RT (min) Area (μV*sec) % Area 
Impurity-J 6.109 78703 100.00 
Impurity-B 32.030 98251 100.00 
Methyl ester 41.293 151585 100.00 
Impurity-E 33.640 153192 100.00 
 
8.3.2. IMPURITY SPIKED SAMPLE     - Figure-15 
 
Impurity Spiked Sample Data 
Compound Name RT (min) Area (μV*sec) 
% 
Area 
Impurity-J 11.583 84160 0.19 
Dexibuprofen 30.738 44393567 98.91 
Impurity-B 32.076 74644 0.17 
Impurity-E 33.473 120949 0.27 
Methyl ester 41.264 154374 0.34 
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8.3.3. FORCED DEGRADATION STUDY 
 
 Figure – 16         Acid Stressed Sample 
 
 
 
 
  
 
 
 
 
 
 
 
Figure – 17                    Alkali Stressed Sample 
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Figure – 18                      Peroxide Stressed sample 
 
 
 
Forced Degradation Study Data–Dexibuprofen 
 
 
Sample Solution 
RT (min) Area (μV*sec) % Area 
Acid stressed 31.123 35941186 99.97 
Alkali stressed 31.053 41997216 99.97 
Peroxide stressed 31.053 41632300 99.95 
Mean 39856900 99.96 
%RSD 13.9 
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8. 4. LIMIT OF DETECTION AND LIMIT OF QUANTITATION [LOD & LOQ] 
 
 Figure – 19                           LOD Solution-1 
 
 
 
 
 
 
  Figure – 20                           LOD Solution-2 
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 Figure – 21                                  LOD Solution-3 
 
Figure – 22                                  LOD Solution-4 
 
 
Figure – 23                                     LOD Solution-5 
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Figure – 24                            LOD Solution-6 
 
 
Figure – 25                            LOQ Solution-1 
 
 
 
 
Figure – 26                          LOQ Solution-2 
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Figure – 27                                       LOQ Solution- 3 
 
 
 Figure – 28                                        LOQ Solution- 4 
 
 
     Figure – 29                                      LOQ Solution- 5 
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Figure – 30                                     LOQ Solution- 6 
 
 
 
 
LOD and LOQ Data for Impurity – J 
 
Test 
Solution 
LOD LOQ 
RT min) Area (μV*sec) % Area RT (min) Area (μV*sec) % Area 
1 6.187 1520 16.22 6.047 3922 18.62 
2 5.893 1616 15.67 6.112 3881 18.92 
3 5.777 1548 14.48 6.150 4030 18.31 
4 6.068 1689 20.06 6.178 3857 18.86 
5 6.023 1661 16.86 6.196 4161 19.72 
6 6.036 1555 18.75 6.203 4032 19.40 
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LOD and LOQ Data for Dexibuprofen 
Test 
Solution 
LOD LOQ 
RT min) Area (μV*sec) % Area RT (min) Area (μV*sec) % Area 
1 31.083 2952 31.49 30.877 5827 27.67 
2 30.202 3365 32.62 31.000 6134 29.90 
3 30.100 3561 33.31 31.112 5880 26.71 
4 30.567 2399 28.50 31.188 5539 27.08 
5 30.761 3291 33.41 31.221 5856 27.75 
6 33.777 2797 33.73 31.252 6059 29.16 
LOD and LOQ Data for Impurity-B 
 
 
 
 
Test 
Solut
ion 
LOD LOQ 
RT 
min) 
Area 
(μV*sec) 
% 
Area 
RT 
(min) 
Area 
(μV*sec) 
% Area 
1 32.181 2052 21.90 31.950 3795 18.02 
2 31.383 2113 20.48 32.073 3517 17.14 
3 31.283 2616 24.46 32.174 3780 17.17 
4 31.767 1714 20.37 32.219 3792 18.54 
5 31.853 2100 21.32 32.256 3805 18.03 
6 31.882 1445 17.42 32.277 3393 16.33 
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LOD and LOQ Data for Impurity-E 
Test 
Solution 
LOD LOQ 
RT min) Area (μV*sec) % Area RT (min) Area (μV*sec) % Area 
1 33.507 1555 16.59 33.292 3691 17.53 
2 32.785 1782 17.28 33.422 3413 16.64 
3 32.517 1419 13.27 33.527 4148 18.84 
4 33.099 1266 15.05 33.581 3618 17.69 
5 33.182 980 9.95 33.613 3806 18.03 
6 33.240 1245 15.02 33.666 3829 18.43 
LOD and LOQ Data for Methyl ester 
Test 
Solution 
LOD LOQ 
RT min) Area (μV*sec) % Area RT (min) Area (μV*sec) % Area 
1 41.216 1293 13.80 41.162 3825 18.16 
2 40.842 1439 13.95 41.216 3568 17.39 
3 40.865 1548 14.48 41.268 4177 18.97 
4 41.071 1348 16.02 41.288 3647 17.83 
5 41.144 1820 18.47 41.039 3476 16.47 
6 41.109 1251 15.09 41.326 3466 16.68 
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8.5.LINEARITY 
Figure – 31              LinearitySolution(LOQlevel) 
 
 
 
 
 
 
 
 
Figure – 32                     LinearitySolution(25%level) 
 
 
 
 
 
 
 
 
 
Figure – 33                       LinearitySolution(50%level) 
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Figure – 34   Linearity Solution(75%level) 
 
 
 
 
 
 
 
 
Figure – 35   Linearity solution(100%level) 
 
 
 
 
 
 
 
 
Figure – 36    Linearitysolution(125%level) 
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Figure – 37     Linearitysolution(150%level) 
 
 
 
 
 
 
 
 
Linearitysolution Data [LOQ and 25%] 
 
Compound 
Name 
Linearitysolution(LOQlev
el) 
Linearitysolution(25%level) 
RT 
(min) 
Area 
(μV*sec) 
% 
Area 
RT 
(min) 
Area 
(μV*sec) 
% 
Area 
Impurity – J 6.186 4282 19.92 6.187 23551 17.63 
Dexibuprofen 31.197 6247 29.05 31.205 24568 18.4 
Impurity - B 32.215 3790 17.63 32.228 21333 15.97 
Impurity – E 
 
33.555 4175 19.42 33.589 32793 24.56 
Methyl ester 41.274 3006 13.98 41.285 31301 23.44 
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Linearitysolution Data [50%and 75%] 
Compound 
Name 
Linearitysolution(50%level) Linearitysolution(75%level) 
RT 
(min) 
Area 
(μV*sec) 
% 
Area 
RT 
(min) 
Area 
(μV*sec) 
% 
Area 
Impurity - J 6.129 45954 17.7 5.803 63758 16.76 
Dexibuprofen 30.849 43196 16.64 29.935 64711 17.01 
Impurity - B 31.901 42494 16.36 31.131 59920 15.75 
Impurity - E 33.224 65157 25.09 32.419 92261 24.25 
Methyl ester 41.055 62864 24.21 40.701 99877 26.25 
 
 
 
Linearitysolution Data [100%and 125% 
Compound 
Name 
Linearitysolution(100% 
level) 
Linearitysolution(125%leve
l) 
RT 
(min) 
Area 
(μV*sec) 
% 
Area 
RT 
(min) 
Area 
(μV*sec) 
% 
Area 
Impurity - J 
5.6
78 
9113
2 17.69 
5.9
16 
11011
2 17.3 
Dexibuprofen 
29.
707 
8621
3 16.73 
30.
482 
10467
6 
16.4
4 
Impurity - B 
30.
96 
8272
1 16.05 
31.
605 
10048
0 
15.7
8 
Impurity - E 
32.
267 
1285
75 24.95 
32.
936 
15759
7 
24.7
6 
Methyl ester 
40.
715 
1266
12 24.57 
40.
995 
16372
9 
25.7
2 
 
 
 
 
 
                                                                                          
CHROMATOGRAMS 
 
Department of Pharmaceutical Analysis Page 89 
 
Linearitysolution Data [150%] 
Compound 
Name 
Linearitysolution(150% level) 
RT (min) Area (μV*sec) % Area 
Impurity - J 5.95 129388 16.99 
Dexibuprofen 30.538 123867 16.26 
Impurity - B 31.652 120845 15.87 
Impurity - E 32.985 185904 24.41 
Methyl ester 41.012 201648 26.48 
 
7.6.ACCURACY 
Figure – 38   LOQ Level 1  
 
 
 
 
 
 
 
 
Figure – 39  LOQ Level 2  
 
 
 
  
 
 
 
Figure – 40  LOQ Level 3  
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Figure – 41  100% Level 1  
 
 
 
 
  
 
 
 
 
Figure – 42                                      100% Level 2  
 
 
 
 
 
 
 
 
Figure – 43  100 % Level 3  
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Figure – 44  150 % Level 1  
 
 
 
 
 
 
 
 
Figure – 45  150 % Level 2  
 
 
 
 
 
 
 
 
Figure – 46  150 % Level 3  
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Accuracy Data : 
 
Solutions  RT 
(min) 
Area 
(μV*sec) 
% Area 
LOQ Level 1 30.848 4821 17.09 
LOQ Level 2 30.767 4854 100.00 
LOQ Level 3 30.796 4880 100.00 
100% Level 1 30.754 85882 100.00 
100% Level 2 30.729 83765 100.00 
100% Level 3 30.789 82342 100.00 
150% Level 1 30.701 123646 100.00 
150% Level 2 30.766 123948 100.00 
150% Level 3 30.250 123074 100.00 
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